Rohner Eliane, Sengayi Mazvita, Goeieman Bridgette, Michelow Pamela, Firnhaber Cynthia, Maskew Mhairi, Bohlius Julia
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.
Int J Cancer. 2017 Aug 1;141(3):488-496. doi: 10.1002/ijc.30749. Epub 2017 May 19.
Data on invasive cervical cancer (ICC) incidence in HIV-positive women and the effect of cervical cancer screening in sub-Saharan Africa are scarce. We estimated i) ICC incidence rates in women (≥18 years) who initiated antiretroviral therapy (ART) at the Themba Lethu Clinic (TLC) in Johannesburg, South Africa, between 2004 and 2011 and ii) the effect of a Pap-based screening program. We included 10,640 women; median age at ART initiation: 35 years [interquartile range (IQR) 30-42], median CD4 count at ART initiation: 113 cells/µL (IQR 46-184). During 27,257 person-years (pys), 138 women were diagnosed with ICC; overall incidence rate: 506/100,000 pys [95% confidence interval (CI) 428-598]. The ICC incidence rate was highest (615/100,000 pys) in women who initiated ART before cervical cancer screening became available in 04/2005 and was lowest (260/100,000 pys) in women who initiated ART from 01/2009 onward when the cervical cancer screening program and access to treatment of cervical lesions was expanded [adjusted hazard ratio (aHR) 0.42, 95% CI 0.20-0.87]. Advanced HIV/AIDS stage (4 versus 1, aHR 1.95, 95% CI 1.17-3.24) and middle age at ART initiation (36-45 versus 18-25 years, aHR 2.51, 95% CI 1.07-5.88) were risk factors for ICC. The ICC incidence rate substantially decreased with the implementation of a Pap-based screening program and improved access to treatment of cervical lesions. However, the risk of developing ICC after ART initiation remained high. To inform and improve ICC prevention and care for HIV-positive women in sub-Saharan Africa, implementation and monitoring of cervical cancer screening programs are essential.
关于撒哈拉以南非洲地区感染艾滋病毒女性的浸润性宫颈癌(ICC)发病率以及宫颈癌筛查效果的数据十分匮乏。我们估计了:i)2004年至2011年期间在南非约翰内斯堡的Themba Lethu诊所(TLC)开始接受抗逆转录病毒治疗(ART)的18岁及以上女性的ICC发病率,以及ii)基于巴氏涂片的筛查项目的效果。我们纳入了10,640名女性;开始接受ART时的中位年龄为35岁[四分位间距(IQR)30 - 42],开始接受ART时的中位CD4细胞计数为113个/µL(IQR 46 - 184)。在27,257人年(pys)期间,有138名女性被诊断为ICC;总体发病率为506/100,000人年[95%置信区间(CI)428 - 598]。在2005年4月宫颈癌筛查可用之前开始接受ART的女性中,ICC发病率最高(615/100,000人年),而在2009年1月以后开始接受ART的女性中发病率最低(260/100,000人年),此时宫颈癌筛查项目以及宫颈病变治疗的可及性得到了扩大[调整后风险比(aHR)0.42,95% CI 0.20 - 0.87]。晚期艾滋病毒/艾滋病阶段(4期对比1期,aHR 1.95,95% CI 1.17 - 3.24)以及开始接受ART时处于中年(36 - 45岁对比18 - 25岁,aHR 2.51,95% CI 1.07 - 5.88)是ICC的危险因素。随着基于巴氏涂片的筛查项目的实施以及宫颈病变治疗可及性的改善,ICC发病率大幅下降。然而,开始接受ART后发生ICC的风险仍然很高。为了为撒哈拉以南非洲地区感染艾滋病毒女性的ICC预防和护理提供信息并加以改善,实施和监测宫颈癌筛查项目至关重要。